{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:02:12Z","timestamp":1791104532633,"version":"4.1.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T00:00:00Z","timestamp":1359936000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0056053","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T21:56:09Z","timestamp":1360014969000},"page":"e56053","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":84,"title":["Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor SB216763, in the Chronic Mild Stress Model of Mice"],"prefix":"10.1371","volume":"8","author":[{"given":"Xian-Cang","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hui","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,2,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders","volume":"7","author":"G Sanacora","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainresrev.2009.05.005","article-title":"Emerging role of glutamate in the pathophysiology of major depressive disorder","volume":"61","author":"K Hashimoto","year":"2009","journal-title":"Brain Res Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2009.02.010","article-title":"Ketamine and the next generation of antidepressants with a rapid onset of action","volume":"123","author":"R Machado-Viera","year":"2009","journal-title":"Pharnmacol Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tips.2009.09.002","article-title":"Glutamate-based antidepressants: 20 years on","volume":"30","author":"P Skolnick","year":"2009","journal-title":"Trends pharmacol Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/10673229.2010.511059","article-title":"Glutamatergic modulators: the future of treating mood disorders?","volume":"18","author":"C Zarate Jr","year":"2010","journal-title":"Harv Rev Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.pnpbp.2010.06.013","article-title":"The role of glutamate on the action of antidepressants","volume":"35","author":"K Hashimoto","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.pbb.2011.04.016","article-title":"Roles of glutamatye signaling in preclinical and\/or mechanistic models of depression","volume":"100","author":"K Tokita","year":"2012","journal-title":"Pharmacol Biochem Beghav"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00345492","article-title":"Increased serum glutamate in depressed patients","volume":"232","author":"JS Kim","year":"1982","journal-title":"Arch Psychiatr Nervenkr"},{"key":"ref9","first-page":"1713","article-title":"Plasma and platelet excitatory amino acids in psychiatric disorders","volume":"150","author":"CA Altamura","year":"1993","journal-title":"Am J Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0006-3223(99)00159-6","article-title":"Reduced glutamate in the anterior cingulate cortex in depression: an <italic>in vivo<\/italic> proton magnetic resonance spectroscopy study","volume":"47","author":"DP Auer","year":"2000","journal-title":"Biol Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/archpsyc.61.7.705","article-title":"Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression","volume":"61","author":"G Sanacora","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2006.03.036","article-title":"Correlation between plasma levels of glutamate, alanine and serine with severity of depression","volume":"30","author":"H Mitani","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.biopsych.2007.03.017","article-title":"Increased levels of glutamate in brains from patients with mood disorders","volume":"62","author":"K Hashimoto","year":"2007","journal-title":"Biol Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archpsyc.64.2.193","article-title":"Reduced prefrontal glutamate\/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy","volume":"64","author":"G Hasler","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145708009516","article-title":"Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response","volume":"12","author":"W Block","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"RM Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an <italic>N<\/italic>-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"CA Zarate Jr","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an <italic>N<\/italic>-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"N Diazgranados","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"ref19","first-page":"939","article-title":"Biol Psychiatry","volume":"71","author":"CA Zarate Jr","year":"2012"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archgenpsychiatry.2010.138","article-title":"<italic>N<\/italic>-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants","volume":"67","author":"JH Krystal","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/ern.10.176","article-title":"Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine","volume":"11","author":"K Hashimoto","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2011.244","article-title":"Ketamine as a novel antidepressant: from synapse to behavior","volume":"91","author":"JW Murrough","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11599770-000000000-00000","article-title":"Ketamine for treatment-resistant unipolar depression: current evidence","volume":"26","author":"SJ Mathew","year":"2012","journal-title":"CNS Drugs"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044","article-title":"Signaling pathways underlying the rapid antidepressant actions of ketamine","volume":"62","author":"RS Duman","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1399-5618.2009.00714.x","article-title":"The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis","volume":"11","author":"R Machado-Vieira","year":"2009","journal-title":"Bipolar Disord"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.euroneuro.2010.02.008","article-title":"The involvement of GSK3\u03b2 in bipolar disorder: integrating evidence from multiple types of genetic studies","volume":"20","author":"JJ Luykx","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref27","first-page":"16","article-title":"Glycogen synthase kinase-3 in the etiology and treatment of mood disorders","volume":"4","author":"RS Jope","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.2174\/138161211797052484","article-title":"The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases","volume":"17","author":"S Amar","year":"2011","journal-title":"Curr Pharm Des"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.biopsych.2004.01.008","article-title":"Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus","volume":"55","author":"O Kaidanovich-Beilin","year":"2004","journal-title":"Biol Psychiatry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1017\/S1461145704004535","article-title":"AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swimming test","volume":"7","author":"TD Gould","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.pnpbp.2008.05.020","article-title":"Antidepressant-like effects of the novel thiadiazolidinone NP031115 in mice","volume":"32","author":"AO Rosa","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/mp.2011.47","article-title":"Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice","volume":"16","author":"E Beurel","year":"2011","journal-title":"Mol Psychiatry"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0006-3223(02)01405-1","article-title":"Preclinical models: status of basic research in depression","volume":"52","author":"EJ Nestler","year":"2002","journal-title":"Biol Psychiatry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd1825","article-title":"The ascent of mouse: advances in modeling human depression and anxiety","volume":"4","author":"JF Cryan","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-5521(00)00025-9","article-title":"Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription","volume":"7","author":"MP Coghlan","year":"2000","journal-title":"Chem Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cell.2008.12.044","article-title":"Disrupted in schizophrenia1 regulates neuronal progenitor proliferation via modulation of GSK3\u03b2\/\u03b2-catenin signaling","volume":"136","author":"Y Mao","year":"2009","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e20955","DOI":"10.1371\/journal.pone.0020955","article-title":"Social isolation-induced aggression potentiates anxiety and depressive-like behavior in male mice subjected to unpredictable chronic mild stress","volume":"6","author":"XC Ma","year":"2011","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"N Li","year":"2010","journal-title":"Science"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate <italic>N<\/italic>-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"N Li","year":"2011","journal-title":"Biol Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bbr.2012.03.027","article-title":"Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse","volume":"231","author":"NM Enman","year":"2012","journal-title":"Behav Brain Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuropharm.2009.03.006","article-title":"Cocaine-induced hyperactivity and sensitization are dependent on GSK3","volume":"56","author":"JS Miller","year":"2009","journal-title":"Neuropharmacology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s002130100687","article-title":"Limitations on the use of the C57BL\/6 mouse in the tail suspension test","volume":"155","author":"AJ Mayorga","year":"2001","journal-title":"Psychopharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0149-7634(05)80194-0","article-title":"Chronic mild stress-induced anhedonia: a realistic animal model of depression","volume":"16","author":"P Willner","year":"1992","journal-title":"Neurosci Biobehav Rev"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s002130050456","article-title":"Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation","volume":"134","author":"P Willner","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000087097","article-title":"Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS","volume":"52","author":"P Willner","year":"2005","journal-title":"Neuropsychobiology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.bjp.0707471","article-title":"Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation","volume":"152","author":"M Selenica","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainresbull.2010.03.005","article-title":"Inhibition of GSK3 attenuates dopamine D<sub>1<\/sub> receptor agonist-induced hyperactivity in mice","volume":"82","author":"JS Miller","year":"2010","journal-title":"Brain Research Bulletin"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.schres.2012.01.024","article-title":"Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine","volume":"136","author":"MH Chan","year":"2012","journal-title":"Schizophrenia Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1460-9568.2002.01899.x","article-title":"In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3beta in neuronal apoptosis: links to tau phosphorylation","volume":"15","author":"W Elyaman","year":"2002","journal-title":"Eur J Neurosci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.npp.1301511","article-title":"The role of Akt-GSK-3\u03b2 signaling and synaptic strength in phencyclidine-induced neurodegeneration","volume":"33","author":"G Lei","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-004-2048-7","article-title":"Forced swimming test in mice: a review of antidepressant activity","volume":"177","author":"B Petit-Demouliere","year":"2005","journal-title":"Psychopharmacology (Berl)"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0056053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T03:34:04Z","timestamp":1540006444000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0056053"}},"subtitle":[],"editor":[{"given":"David A.","family":"Slattery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,4]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0056053","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,4]]}}}